Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
Open Access
- 25 October 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 27 (2) , 128-134
Abstract
Objectives: To characterize the blood pressure (BP) profile of the new β3-adrenergic receptor agonist, vibegron, in patients with overactive bladder. Methods: Patients were randomized to once-daily vibegron 75 mg or placebo for 28 days and underwent ambulatory BP monitoring. The primary endpoint was change from baseline (CFB) to day 28 in mean daytime ambulatory systolic BP (SBP). Secondary endpoints were CFB in mean 24-h SBP and in mean daytime and mean 24-h ambulatory diastolic BP (DBP) and heart rate (HR). Safety was assessed through adverse event reporting. Results: Of 214 patients randomized, 96 receiving vibegron and 101 receiving placebo had evaluable baseline and day 28 measurements. Overall, 39.6 and 30.7% of patients receiving vibegron and placebo, respectively, had preexisting hypertension. The least squares mean difference (LSMD; 90% confidence interval) between vibegron and placebo in CFB in mean daytime SBP was 0.8 (–0.9, 2.5) mmHg. LSMD in CFB in mean daytime DBP and HR was 0.0 mmHg and 0.9 bpm, respectively. No significant differences between treatments were seen in CFB in mean 24-h SBP (LSMD, 0.6 mmHg), DBP (–0.2 mmHg) or HR (1.0 bpm). The most common treatment-emergent adverse event was hypertension, with rates comparable between groups [vibegron: n = 5 (4.7%); placebo: n = 4 (3.7%)]. One patient receiving vibegron took a prohibited medication (phentermine) known to increase BP. Conclusions: Once-daily vibegron had no statistically significant or clinically relevant effects on BP or HR.Keywords
This publication has 16 references indexed in Scilit:
- Cardiovascular effects of antimuscarinic agents in overactive bladderExpert Opinion on Drug Safety, 2013
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical ApplicationCardiology, 2012
- Presence of central nervous system, cardiovascular and overall co‐morbidity burden in patients with overactive bladder disorder in a real‐world settingBJU International, 2011
- National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and AgeUrology, 2011
- Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladderBJU International, 2010
- Expression and functional role of β-adrenoceptors in the human urinary bladder urotheliumNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- β3-adrenoceptors in human detrusor muscleUrology, 2002
- Association Between Blood Pressure Level and the Risk of Myocardial Infarction, Stroke, and Total MortalityArchives of internal medicine (1960), 2001